Hosted on MSN11mon
Immuneering doses first subject in Phase I/IIa solid tumour trial
pathway, IMM-6-415, will be evaluated as an oral, twice-daily treatment. Patients with rapidly accelerated fibrosarcoma (RAF), kirsten rat sarcoma (KRAS), neuroblastoma RAS (NRAS), or Harvey RAS ...
Nature15d
Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule
Apoptosis is dependent on caspase activation, whereas the caspase-independent necrotic signaling pathway remains largely ... in a highly sensitive fibrosarcoma cell line, Fas triggers cell death ...